Dr Barbara Pistilli et Stefan Michiels : « Le taux de TIL pourrait permettre une désescalade dans le cancer du sein triple négatif » lequotidiendumedecin.fr/specialites/ca…

Two phase III randomized trials in metastatic BC and GIST will be presented next week during the ⁦ESMO - Eur. Oncology⁩ Virtual Plenary sessions in partnership with ⁦AACR⁩ . May 9th or 10th esmo.org/meeting-calend…

📰 Kick-off de l’IHU Prism Center :

Ce jeudi 2 mai s’est tenu à l’espace Maurice Tubiana de Gustave Roussy le kick-off de l’IHU #Prism , cofondé par CentraleSupélec, Gustave Roussy, l’Inserm, Unicancer et l’ Université Paris-Saclay.

Lire l'actualité ➡ gustaveroussy.fr/fr/kick-de-lih…

During the visit, our chief clinician, Charles Swanton, highlighted some of the innovative research that Cancer Research UK is supporting at the hospital, including our single biggest investment in lung cancer research, TRACERx.

It’s been lovely to hear how much the visit meant to patients…

Thank you Vivek for the outstanding talk during the kick-off of the PRISM center. Your vision and capacity building generated a lot of attention and entousiasm from the participants

The kick-off Meeting of the Prism Center IHU-A will be on Thursday May 2nd. It’s an opportunity to organise a nice seminar around Precision Medicine w Vivek Subbiah, MD & Nicholas McGranahan as speakers. you are welcome to join us (+ there is a cocktail at the end 🥂🧉🍹🥤🧃🍵☕️ !)

.⁦ESMO - Eur. Oncology⁩ is launching a monthly virtual journal club. 3 papers discussed during 1h by the best experts. The goal is to update all colleagues about the latest advances wherever they are in the 🌍. First session on May ! Stay connected ! esmo.org/about-esmo-mee…

Very interesting #ESMOYOC #YO4YO session later today…looking forward to seeing you online !!!

ESMO - Eur. Oncology OncoAlert Maria Kfoury Véronique Debien Joseph Ciccolini Università di Genova Ospedale San Martino Genova francescalongo Evandro de Azambuja, MD, PhD Andres Cervantes

Unequity is the key word from the breast cancer The Lancet commission. A roadmap is proposed. ↘️ these unequities will have measurable impact on BC Survival globally. by charlotte Coles et al. V happy to have participated with Franzoi Maria Alice & Ines Vaz Luis, MD from Gustave Roussy

The #PrecisionOncology webinar presents ESMO’s new proposal for a classification of tissue-agnostic therapeutics. Register now for free and take part in this live interaction with international experts.

And that is a wrap for the Transatlantic conference between Dana-Farber Gustave Roussy around the topic of “liquid biopsies”—thank you to all the faculty, @medscape + Servier

See you next year in Paris !
#

Original Article: Alectinib in Resected ALK-Positive Non–Small-Cell Lung Cancer (ALINA) nej.md/3VUzf3M

Editorial: Adjuvant Alectinib in ALK-Rearranged NSCLC — Here and Now nej.md/43WM3bU

#Oncology

It's today! Are you not in #Boston ❓No worries‼️It is a hybrid event! 👇

events.medscapelive.org/website/68476/

Medscape Dana-Farber Dana-Farber_GU Gustave Roussy Toni Choueiri, MD FabriceAndre

TILs = better outcome in pts with early stage TNBC who did NOT receive chemo (n=1966). A study by S Michiels ⁦Gustave Roussy⁩ and col.
Rationale for the ETNA trial testing chemo-free tt in pts with ↗️ TILs / eTNBC led by ⁦Barbara Pistilli⁩ jamanetwork.com/journals/jama/…

.Ines Vaz Luis, MD will receive a Special Award of ASCO for her role as a Mentor. She has developed a unique team of MDs, social scientists, data scientists, pts. This award illustrates the efforts of Gustave Roussy to train a new generation of colleagues.

Merci a tous les soutiens pour mon #SemiParis au profit de Gustave Roussy . Le parcours est genial mais la fin est hyper dure a cause des crampes 😩🥵

Out in ESMO Open our review on precision medicine in #breastcancer :
📍milestones of genomics to predict drug sensitivity
📍new dimensions of cancer biology
📍future directions of precision medicine
Fernanda Mosele FabriceAndre Stefan Michiels Gustave Roussy
doi.org/10.1016/j.esmo…

#RareDiseaseDay : 1 in 5 cancers are rare. The EU must act now and continue after the 2024 elections to overcome challenges for patients, researchers and healthcare professionals.
📌esmo.org/policy/rare-ca…

#ESMOTAT24 is the conference dedicated to drug development, with a large participation of Biotech / Pharma to the Scientific program and Forums of discussion. Hot topics this year were ctDNA for drug dvlpt, EU IVDR, biotech investments, dosage & comb optimisation, new Endpoints…

Ce dimanche, je courrai (lentement…) le semi marathon avec un dossard « Don Gustave Roussy « . Si certains d’entre vous veulent participer via un don ca serait genial 👇. semi-paris.dossards-solidaires.org/fundraisers/fa…